Related Experiment Videos
Current status of allogeneic bone marrow transplantation
K A Sobocinski1, M M Horowitz, A A Rimm
1Division of Biostatistics/Clinical Epidemiology, Medical College of Wisconsin, Milwaukee 53226.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|January 1, 1992
Summary
Allogeneic bone marrow transplants are increasingly used for hematologic diseases, including leukemia and aplastic anemia. Risk factor assessment aids in predicting and managing post-transplant complications, improving patient outcomes.
Area of Science:
- Hematology
- Transplantation Immunology
Background:
- Allogeneic bone marrow transplantation (BMT) is a critical therapy for various hematologic malignancies and genetic disorders.
- The use of BMT has significantly increased, with a substantial rise in procedures between 1988-1990.
- Historically, BMT was limited by the need for HLA-identical sibling donors and significant complications.
Purpose of the Study:
- To summarize current data on allogeneic bone marrow transplants from the International Bone Marrow Transplant Registry (IBMTR).
- To identify key risk factors influencing the outcomes of bone marrow transplantation.
- To provide insights into the evolving landscape of BMT, including the use of alternative donors.
Main Methods:
- Analysis of data from the IBMTR covering a 36-year period (1955-1990).
- Review of transplant trends, indications, and outcomes.
- Identification and assessment of risk factors associated with post-transplant complications.
Main Results:
- Over 33,000 allogeneic bone marrow transplants were performed between 1955 and 1990.
- A significant increase in transplant volume was observed in recent years (1988-1990).
- The use of unrelated or HLA-partially matched related donors has shown some success, expanding donor options.
Conclusions:
- Allogeneic bone marrow transplantation is an established and growing treatment modality for severe hematologic and immune disorders.
- Graft failure, graft-versus-host disease (GVHD), and interstitial pneumonia remain significant challenges.
- Risk factor assessment is crucial for predicting and mitigating complications, thereby improving BMT success rates.